The company's approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. With that, the stock is performing so well that it appears to outdone other sector peers. This would seems to me that this stock may outperform the market over the next one to three months and continue bullish and hold ATH ranking. Maybe this delivers good news for everyone, right?